Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 163 |
| Active Pipeline (Recruiting Now) | 90 (54) |
| Completed vs Stopped Early | 44 / 29 (17.8%) |
| Median Closed Actual Enrollment | 89 participants |
| Physical Hospital Site Disclosure | 99.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 9 (6 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Samsung Medical Center | Seoul, Gangnam-Gu | 19 |
| Seoul National University Hospital | Seoul | 18 |
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 18 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Phase III | RECRUITING |
| NCT06091865 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, i | Phase III | RECRUITING |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Che | Phase III | RECRUITING |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patie | Phase II | RECRUITING |
| NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Regeneron Pharmaceuticals Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.